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Abstract
Background: Low bone mineral density (BMD) represents a major risk factor for bone frac-
tures in patients with chronic kidney disease (CKD) as well as after kidney transplantation. 
However, modalities to solidly predict patients at fracture risk are yet to be defined. Better 
understanding of bone turnover biomarkers (BTMs) may close this diagnostic gap. This study 
strives to correlate BTMs to BMD in kidney transplant recipients. Methods: Changes in BTMs 
– procollagen type I N-terminal propeptide (P1NP), bone-specific alkaline phosphatase (BSAP), 
β-isomer of the C-terminal telopeptide of type I collagen, and urine deoxypyridinoline/Cr – at 
the time of transplant and 3 months were correlated to changes in BMD measured by dual-
energy X-ray absorptiometry at the time of transplant, 6, and 12 months, respectively. Half of 
the collective was treated with denosumab twice yearly in addition to the standard treatment 
with calcium and vitamin D. Results: Changes in bone formation markers BSAP and P1NP 
within 3 months showed a significant negative correlation to changes in BMD at the hip with-
in 6 months in denosumab-naïve patients. This correlation was abrogated by denosumab 
treatment. Conclusions: Changes in BSAP and P1NP showed promise in short-term prediction 
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of BMD. We suggest further trials expanding on the knowledge of these BTMs with assess-
ment of fracture risk, sequential measurements of BTMs within the first 6 months, and the 
additional use of computed tomography to assess BMD. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Chronic kidney disease (CKD) is accompanied by relevant changes in bone and mineral 
metabolism which can lead to renal osteodystrophy [1]. The high prevalence of bone disease 
in patients with CKD implicates that kidney transplant candidates often present with osteo-
penia or osteoporosis. The already low bone mineral density (BMD) may further decrease 
after transplantation, especially in the first year after transplantation and mainly because of 
glucocorticoids. They have a powerful detrimental effect on the skeleton by several mecha-
nisms and are still a main pillar of immunosuppression after transplantation [2]. In addition, 
pre- and posttransplant hyperparathyroidism leads to a mechanical compromise of the bone 
[3]. Therapeutic amelioration of bone loss after kidney transplantation includes the supple-
mentation of calcium and vitamin D [4, 5]. Another controversially discussed treatment 
constitutes bisphosphonates, which indeed improve bone loss, but are giving cause to several 
concerns, including nephrotoxicity. Controversial data on fracture prevention in renal trans-
plant recipients and the occurrence of atypical fractures in these patients impede their wide-
spread application [6–14]. The RANKL antibody denosumab represents a newer strategy in 
preventing posttransplant bone loss, which had superior efficacy in improving BMD and 
preventing fractures in postmenopausal women with osteoporosis as compared to bisphos-
phonates [15, 16].
Dual-energy X-ray absorptiometry (DXA) scan represents the gold standard to diagnose 
osteoporosis and its severity, but it suffers from methodological limitations [17]. In contrast, 
bone turnover biomarkers (BTMs) can possibly identify patients with rapid bone loss [18, 19] 
and may assist in monitoring treatment efficacy before BMD decline becomes obvious by 
DXA. Ability of early BMD loss recognition with establishment of timely treatment may further 
reinforce patient compliance. Nevertheless, current expert consensus states that BTMs should 
not guide BMD surveillance solely but may monitor osteoporosis treatment efficacy. Wide-
spread application is hampered by their biological variability [20–23] and controversial data 
of fracture prediction [24].
In the POSTOP trial by Bonani et al. [25], a total of 4 BTMs apart from the parathyroid 
hormone (PTH) were studied: 2 markers of bone formation, procollagen type I N-terminal 
propeptide (P1NP) and bone-specific alkaline phosphatase (BSAP), and 2 markers of bone resorption, β-isomer of the C-terminal telopeptide of type I collagen (β-CTX), and urine 
deoxypyridinoline/Cr (DPD). BTMs are not specific for a single bone disease and reflect the 
entire skeleton [26]. P1NP is a specific by-product of active osteoblasts. The extension peptide 
P1NP is cleaved by enzymes at the end of the procollagen molecule during the formation of 
bone matrix [23]. It has been recommended by the Bone Marker Standards Working Group 
because of its low inter-individual variability [23] and its stability in serum at room temper-
ature [27]. BSAP on the other hand is a specific product of bone osteoblasts as well but reflects 
enzymatic activity. Osteoid mineralization is mediated by alkaline phosphatase secreted by 
osteoblasts [23].
Most of the bone resorption markers are degradation products of bone collagen. The 
pyridinium cross-links DPD are a by-product during bone maturation and are released during the bone resorption process. The same holds true for the peptide β-CTX of the type I collagen 
molecule [23]. β-CTX surfaced as the marker of choice, although it has a large circadian vari-
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ation with the requirement of a morning fasting blood sample for accurate interpretation [23, 
28].
The POSTOP study group was able to show an increase in BMD measured by DXA after 
twice-yearly denosumab in the first year after kidney transplantation. Moreover, a significant 
decrease of all studied BTMs was documented in the denosumab group [25]. This post hoc 
analysis of the POSTOP trial aims to investigate whether the changes in the BMD at the lumbar 
spine and total hip at 6 and 12 months can be predicted by the changes in BTMs at 3 months.
Materials and Methods
Patients and Study Design
This study is a post hoc analysis of the POSTOP trial by Bonani et al. [25] (Effect of Twice-
Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant 
Recipients: a Randomized Controlled Trial). The POSTOP trial was a 1-year prospective single-
center, randomized, parallel-group, open-label clinical trial in de novo kidney transplant recip-
ients. The study was approved by the local ethics steering committee, conformed to the Decla-
ration of Helsinki and Istanbul, and has been registered with ClinicalTrials.gov (NCT01377467).
Included patients were adult woman and man with end-stage renal disease (ESRD). 
Transplantation took place up to 28 days previously with a kidney allograft and patients were 
treated with standard immunosuppression, that is, calcineurin antagonist, mycophenolate, 
and corticosteroids. Patients had to be excluded if there was evidence of a poor or unstable graft function (Cr >200 μmol/L), severe osteoporosis (T-score below −4.0), severe hyper or 
hypoparathyroidism (iPTH >800 or <10 ng/L), and hypo or hypercalcemia (total calcium <1.8 
or >2.7 mmol/L). Randomization followed a 1:1 protocol to the denosumab group (60 mg 
denosumab s.c. at baseline and after 6 months) or no treatment. The investigators of the 
biomarker measurements were masked to allocation. Serum and urine samples were collected 
from all patients at baseline and after 3, 6, and 12 months. The analyzed BTMs included P1NP, BSAP, β-CTX, and DPD.
Laboratory Measurements
Standard laboratory techniques were used to assess levels of BTMs as prior described 
[29]. The eGFR was calculated according to the CKD-EPI formula.
Dual-Energy X-Ray Absorptiometry
Measurements of BMD were obtained by DXA at baseline and at 6 and 12 months in all 
patients. Two anatomic sites were assessed: first, the lumbar spine constituting of averages 
between vertebrae L1 to L4 and, second, the proximal femur (total hip). The examination was 
conducted with a Hologic QDR 4500 A device, and the results were expressed as a relative 
value in the number of SD below the expected normal gender- and ethnicity-adjusted BMD 
values (T-Score).
Statistical Analyses
All data were analyzed using R version 3.6.1. Percentage change of BMD was calculated 
between baseline and visits at 6 and 12 months; absolute change was computed for all 
biomarkers between baseline and visit at 3 months. Spearman’s rho between biomarkers and 
BMD was appraised between the control and denosumab group with the package “Hmisc” 
[30], and all p values were Holm corrected within treatment groups. The figures were plotted 
with the package “ggplot2” [31].
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Results
A total of 90 kidney transplant recipients with a functioning graft were included (Fig. 1). 
After transplantation, patients were randomized to denosumab group (60 mg s.c. at baseline 
and at 6 months, n = 46) or control group receiving no treatment (n = 44). Baseline charac-
teristics were balanced between the 2 groups excepting gender with a majority of men in the 
denosumab group resulting in a higher baseline BMD (Table 1). The mean age of the patients 
was 49.0 ± 12.9 years, roughly two-third were male (63.3%). Most study participants in both 
Fig. 1. Study flow chart.





Age, years 49.0±12.9 50.0±14.0
Men, n (%) 22 (50.0) 35 (76.1)
White ethnicity, n (%) 42 (95.5) 44 (95.7)
Repeat transplantation, n (%) 7 (15.9) 7 (15.2)
BMD and T-scores
Total lumbar spine BMD, g/cm2 0.934±0.129 1.002±0.139
Total lumbar spine T-score −1.27±1.15 −0.67±1.25
Total hip BMD, g/cm2 0.847±0.092 0.925±0.132
Total hip T-score −1.05±0.65 −0.59±0.97
Osteopenic patients, n (%) 25 (56.8) 16 (34.8)
Osteoporotic patients, n (%) 6 (13.6) 3 (6.5)
P1NP, µg/L 75.3±44.4 66.6±51.6
BSAP, µg/L 15.7±13.9 13.5±14.8β-CTX, µg/L 0.8±0.4 0.6±0.3
DPD, nmol/mmol 8.2±2.7 7.2±3.0
PTH, ng/L 147.6±137.1 163.2±153.5
Data are mean ± SD, or n (%). PTH, parathyroid hormone; BSAP, bone-specific alkaline phosphatase; P1NP, procollagen-1 N-terminal propeptide; β-CTX, β-isomer of C-terminal telopeptide of type I collagen; 
DPD, urine deoxypyridinoline/Cr.
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groups were Caucasian (95.6%) and had been transplanted for the first time (84.4%). All 
patients were prescribed standard treatment for posttransplant CKD-MBD consisting of 
calcium (control group 619 ± 475 mg q.d., denosumab group 756 ± 609 mg q.d.) and vitamin 
D supplementation (control group 1,400 ± 1,295 IU q.d., denosumab group 1,526 ± 946 IU 
q.d.). During the study, 2 patients in the denosumab group received cinacalcet. No other medi-
Table 2. Time-dependent BMD and bone markers’ behavior
Parameter Baseline 3 months 6 months 12 months
Control (n = 44)
Total lumbar spine BMD, g/cm2 0.934±0.129 0.922±0.135 0.933±0.136
Total hip BMD, g/cm2 0.847±0.092 0.847±0.095 0.854±0.100
P1NP, µg/L 75.3±44.4 106.9±89.9
BSAP, µg/L 15.7±13.9 15.9±10.6β-CTX, µg/L 0.8±0.4 0.6±0.4
DPD, nmol/mmol 8.2±2.7 7.2±3.5
PTH, ng/L 147.6±137.1 113.0±84.5
Denosumab (n = 46)
Total lumbar spine BMD, g/cm2 1.002±0.139 1.033±0.140 1.054±0.140
Total hip BMD, g/cm2 0.925±0.132 0.941±0.132 0.955±0.130
P1NP, µg/L 66.6±51.6 40.8±34.8
BSAP, µg/L 13.5±14.8 8.6±7.2β-CTX, µg/L 0.6±0.3 0.1±0.1
DPD, nmol/mmol 7.2±3.0 5.0±1.6
PTH, ng/L 163.2±153.5 167.2±173.6
Data are mean ± SD. PTH, parathyroid hormone; BSAP, bone-specific alkaline phosphatase; P1NP, procol-lagen-1 N-terminal propeptide; β-CTX, β-isomer of C-terminal telopeptide of type I collagen; DPD, urine 
deoxypyridinoline/Cr.
Table 3. Correlation of bone formation and resorption markers (absolute change) after 3 months and BMD 
measured at lumbar spine and hip (percentage change) after 6 and 12 months of follow-up








P1NP control −0.388 [0.167] −0.484a [0.022] −0.010 [1.000] −0.214 [1.000]
P1NP denosumab −0.293 [0.966] −0.046 [1.000] −0.240 [1.000] +0.042 [1.000]
BSAP control −0.506a [0.013] −0.476a [0.026] −0.075 [1.000] −0.238 [1.000]
BSAP denosumab −0.258 [1.000] −0.035 [1.000] −0.128 [1.000] −0.026 [1.000]
DPDb control −0.476 [0.075] −0.296 [1.000] −0.212 [1.000] −0.160 [1.000]
DPDb denosumab −0.363 [0.561] −0.209 [1.000] −0.376 [0.524] −0.156 [1.000]β-CTX control −0.298 [0.769] −0.408 [0.116] −0.040 [1.000] −0.121 [1.000]β-CTX denosumab −0.102 [1.000] −0.104 [1.000] −0.115 [1.000] −0.203 [1.000]
PTH control +0.129 [1.000] +0.103 [1.000] −0.102 [1.000] +0.010 [1.000]
PTH denosumab +0.076 [1.000] +0.162 [1.000] −0.330 [0.627] −0.082 [1.000]
Data depicted as Spearman’s rho [p value]. P1NP, procollagen-1 N-terminal propeptide; BSAP, bone-specific alkaline phosphatase; DPD, urine deoxypyridinoline/Cr; β-CTX, β-isomer of C-terminal telopeptide 
of type I collagen; PTH, parathyroid hormone. a Significance met by p ≤ 0.05 (p values are Holm corrected 
within the treatment group). b DPD had up to 15% missing values and in consequence even moderate 
correlations did not prove to be significant.
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cations with influence on the bone metabolism were used. At baseline, 10% of the patients 
were osteoporotic and 45% were osteopenic.
The Bone Formation Markers: BSAP and P1NP
Descriptive values of the bone formation markers at baseline as well as 3 months later 
are shown in Table 2. Change in levels of BSAP and P1NP after 3 months inversely correlated 
with the variation of BMD of the hip after 6 months in the control group. This was also seen 
for BSAP at lumbar spine. However, significance was not met for any site or biomarker in the 
denosumab group. Neither was any predictive value documented for the longer observation 
period over 12 months (Table 3; Fig. 2, 3).
The Bone Resorption Markers: β-CTX, DPD, and PTH
Descriptive values of bone resorption markers at baseline as well as 3 months later are 
shown in Table 2. None of the investigated bone resorption markers showed any significant 
correlation to change of BMD. This holds true for both control and denosumab group patients, 
as well as for both studied sites and time frames (Table 3).
Discussion
Renal osteodystrophy is a prevalent disorder in CKD, causing higher morbidity with 
reduction in quality of life and higher mortality [32]. After kidney transplantation, several 
additional detrimental factors reduce BMD on top of the pre-existing damage [3]. Hence, the 
Fig. 2. Correlation of BSAP and BMD in denosumab-naïve patients. Dots show the absolute change in BSAP 
at 3 months versus the percentage change in BMD at 6 months and the line shows the average trend by using locally weighted regression (loess) with a span (degree of smoothing) of 0.85. Spearman’s rho was −0.476 for total hip and −0.506 for lumbar spine. BSAP, bone-specific alkaline phosphatase; BMD, bone mineral den-
sity.
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prevention of osteoporosis or at least maintenance of BMD constitutes a very important role 
in posttransplantation management.
Loss of BMD is most rapid in the first 6–12 months after kidney transplantation [13]; 
therefore, early therapy strategies with denosumab, for example, are paramount [25]. 
Predictive markers of future BMD decline are necessary to best select patients in need of 
constant monitoring and aggressive treatment. This post hoc analysis aims to shed light on 
whether BTMs may be able to close this gap in diagnostics.
The current study documented a moderate negative correlation in denosumab-naïve 
patients in both studied bone formation markers after 3 months and BMD measured at the 
hip after 6 months. In contrast to P1NP, this finding holds true for BSAP and change of BMD 
at lumbar spine in the same time frame. No predictive value was documented for the studied 
bone resorption markers.
In a recent study by Keronen et al. [33], no correlation between the studied BTMs, that 
is, PTH, BSAP, osteoclastin, and BMD or bone histomorphometric findings was found in 
kidney-transplanted and dialysis patients, although bone formation and mineralization 
declined in the late posttransplant period. This finding of declining BMD is supported by 
similar data from an observational, prospective study by Evenepoel et al. [34]. Our analysis 
documented failure of BMD prediction for the 2 additional bone resorption markers DPD and β-CTX. In contrast to their findings, our study showed a moderate negative correlation 
between BSAP and BMD development. Furthermore, the intervals from baseline to the follow-
up measurement of BTMs were 1 and 2 years, respectively. In the longer period after trans-
plantation, that is, 12 months and beyond, all of the analyzed BTMs in our study equally failed 
to show a correlation. Strikingly, this emphasizes the importance of short-term predictors of 
Fig. 3. Correlation of P1NP and BMD in denosumab-naïve patients. Dots show the absolute change in P1NP 
at 3 months versus the percentage change in BMD at 6 months and the line shows the average trend by using locally weighted regression (loess) with a span (degree of smoothing) of 0.85. Spearman’s rho was −0.484 for total hip and −0.388 for lumbar spine. P1NP, procollagen-1 N-terminal propeptide; BMD, bone mineral 
density.
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BMD development as documented in our study with the possibility of timely drug inter-
vention in vulnerable patients.
Contrary to kidney transplantation, several valuable studies on BTMs in CKD patients are 
available. Varying patient cohorts, incomparable methods, and inconsistent results impede 
direct correlation to this study: In a trial focusing on all stages of CKD by Nickolas et al. [35], 
the studied BTMs failed to forecast changes in BMD measured by DXA. Interestingly, the study 
documented a correlation between the elevation of BTMs, including PTH and cortical dete-
rioration assessed by high-resolution peripheral quantitative computed tomography at 
radius and tibia. This finding was confirmed in a dialysis collective by Malluche et al. [19] 
Additionally, they were able to document a predictive value of P1NP on bone gain in the spine 
by assessment with quantitative computed tomography. In patients with CKD, application of 
computed tomography for the assessment of BMD may catch momentum in the future due to 
mismeasurements using DXA in this population [19, 36–38]. The missing correlation of BTMs 
and lumbar spine BMD as compared to total hip in our data may be attributed to an accuracy 
error of DXA due to extensive calcification of the aorta in kidney transplant recipients [17].
Furthermore, contemporary treatment options for the mitigation of BMD loss also impact 
the levels of BTMs. Treatment of postmenopausal women with denosumab revealed a larger 
decrease of CTX and P1NP than those with alendronate [39]. This matches with the obser-
vation of a decrease of BTMs under denosumab treatment as compared to placebo control in 
kidney-transplanted patients [25]. Our data obtained from denosumab-treated patients failed to establish a correlation between BMD at any given time or site and β-CTX or P1NP. 
Brown et al. showed a low point of CTX under denosumab treatment as early as 1 month after application  [39]. It may be hypothesized that a correlation of BMD and β-CTX may have been 
missed due to the delayed measurement after 3 months in our study design. However, limited 
comparability of osteoporosis in postmenopausal women and renal osteodystrophy may 
constitute an important caveat.
Our study had several limitations: First, there was a marginal imbalance in patient char-
acteristics between the two groups. Second, lack of bone biopsies prohibited correlation of 
histomorphometric findings to BTM levels. Furthermore, assessment of BMD was only done 
by DXA, and no second modality such as high-resolution peripheral quantitative computed 
tomography was performed. Last but not least, the follow-up period and sample size did not 
allow for an investigation of fracture risk, which would represent the most relevant end point 
from a clinician’s perspective.
In conclusion, we found a negative correlation between the early change of P1NP as well 
as BSAP and development of BMD at the hip after 6 months of kidney transplantation. This 
effect was abrogated by denosumab treatment. Among many factors leading to challenging 
comparability of data, the heterogeneity of renal osteodystrophy itself [1], the high pre-
analytic and biologic variability of BTMs [23], and the differences of measurement modalities 
are paramount. Further investigation is warranted to clarify whether BTM-based estimation 
of BMD translates into a correctly assessed risk of fracture and, in the long run, into biochem-
ically guided individual treatment options. We suggest further studies with the four afore-
mentioned BTMs, early sequential measurements within the first 6 months of treatment, and 
a broadening of diagnostic modalities with computed tomography. Last, understanding of 
both changes in microscopic bone structure and biochemical turnover is of tremendous 
importance to attempt sound prediction of skeleton health in patients with renal insuffi-
ciency. Therefore, as of now, we concur with current expert consensus to refrain from BMD 
prediction solely by BTMs. Moreover, the increased use of denosumab in kidney transplant 
recipients may further complicate BTM interpretation.
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